Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene and MEI Pharma to Test Drug Combination Therapy in B-Cell Malignancies

publication date: Oct 11, 2018

BeiGene will collaborate with MEI Pharma of San Diego to test MEI's ME-401, a PI3K delta inhibitor, in combination with BeiGene's BTK inhibitor in patients with B-cell malignancies. MEI will amend its ongoing Phase Ib trial to include evaluation of zanubrutinib, BeiGene's BTK inhibitor, in combination with ME-401 in B-cell malignancy patients. The costs of the trial will be shared equally by the two companies; both will supply clinical supplies of their respective candidates; and each company will retain full commercial rights to their own product. More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160) (NSDQ: MEIP)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.